Literature DB >> 16024784

Transformation of human and murine fibroblasts without viral oncoproteins.

Jesse S Boehm1, Meghan T Hession, Sara E Bulmer, William C Hahn.   

Abstract

Murine embryo fibroblasts are readily transformed by the introduction of specific combinations of oncogenes; however, the expression of those same oncogenes in human cells fails to convert such cells to tumorigenicity. Using normal human and murine embryonic fibroblasts, we show that the transformation of human cells requires several additional alterations beyond those required to transform comparable murine cells. The introduction of the c-Myc and H-RAS oncogenes in the setting of loss of p53 function efficiently transforms murine embryo fibroblasts but fails to transform human cells constitutively expressing hTERT, the catalytic subunit of telomerase. In contrast, transformation of multiple strains of human fibroblasts requires the constitutive expression of c-Myc, H-RAS, and hTERT, together with loss of function of the p53, RB, and PTEN tumor suppressor genes. These manipulations permit the development of transformed human fibroblasts with genetic alterations similar to those found associated with human cancers and define specific differences in the susceptibility of human and murine fibroblasts to experimental transformation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16024784      PMCID: PMC1190359          DOI: 10.1128/MCB.25.15.6464-6474.2005

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  60 in total

1.  Telomerase catalytic subunit homologs from fission yeast and human.

Authors:  T M Nakamura; G B Morin; K B Chapman; S L Weinrich; W H Andrews; J Lingner; C B Harley; T R Cech
Journal:  Science       Date:  1997-08-15       Impact factor: 47.728

2.  Identification of kinase-phosphatase signaling modules composed of p70 S6 kinase-protein phosphatase 2A (PP2A) and p21-activated kinase-PP2A.

Authors:  R S Westphal; R L Coffee; A Marotta; S L Pelech; B E Wadzinski
Journal:  J Biol Chem       Date:  1999-01-08       Impact factor: 5.157

3.  Creation of human tumour cells with defined genetic elements.

Authors:  W C Hahn; C M Counter; A S Lundberg; R L Beijersbergen; M W Brooks; R A Weinberg
Journal:  Nature       Date:  1999-07-29       Impact factor: 49.962

4.  Expression of catalytically active telomerase does not prevent premature senescence caused by overexpression of oncogenic Ha-Ras in normal human fibroblasts.

Authors:  S Wei; S Wei; J M Sedivy
Journal:  Cancer Res       Date:  1999-04-01       Impact factor: 12.701

5.  Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF.

Authors:  T Kamijo; F Zindy; M F Roussel; D E Quelle; J R Downing; R A Ashmun; G Grosveld; C J Sherr
Journal:  Cell       Date:  1997-11-28       Impact factor: 41.582

6.  Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span.

Authors:  H Vaziri; S Benchimol
Journal:  Curr Biol       Date:  1998-02-26       Impact factor: 10.834

7.  Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation.

Authors:  R A Greenberg; R C O'Hagan; H Deng; Q Xiao; S R Hann; R R Adams; S Lichtsteiner; L Chin; G B Morin; R A DePinho
Journal:  Oncogene       Date:  1999-02-04       Impact factor: 9.867

8.  Direct activation of TERT transcription by c-MYC.

Authors:  K J Wu; C Grandori; M Amacker; N Simon-Vermot; A Polack; J Lingner; R Dalla-Favera
Journal:  Nat Genet       Date:  1999-02       Impact factor: 38.330

9.  Dissociation among in vitro telomerase activity, telomere maintenance, and cellular immortalization.

Authors:  C M Counter; W C Hahn; W Wei; S D Caddle; R L Beijersbergen; P M Lansdorp; J M Sedivy; R A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

10.  Myc activates telomerase.

Authors:  J Wang; L Y Xie; S Allan; D Beach; G J Hannon
Journal:  Genes Dev       Date:  1998-06-15       Impact factor: 11.361

View more
  83 in total

1.  Cervical keratinocytes containing stably replicating extrachromosomal HPV-16 are refractory to transformation by oncogenic H-Ras.

Authors:  Kristi L Berger; Felicia Barriga; Michael J Lace; Lubomir P Turek; Gideon J Zamba; Frederick E Domann; John H Lee; Aloysius J Klingelhutz
Journal:  Virology       Date:  2006-08-30       Impact factor: 3.616

2.  Wild-type NRas and KRas perform distinct functions during transformation.

Authors:  Poppy P Fotiadou; Chiaki Takahashi; Hasan N Rajabi; Mark E Ewen
Journal:  Mol Cell Biol       Date:  2007-07-16       Impact factor: 4.272

3.  mTOR drives its own activation via SCF(βTrCP)-dependent degradation of the mTOR inhibitor DEPTOR.

Authors:  Daming Gao; Hiroyuki Inuzuka; Meng-Kwang Marcus Tan; Hidefumi Fukushima; Jason W Locasale; Pengda Liu; Lixin Wan; Bo Zhai; Y Rebecca Chin; Shavali Shaik; Costas A Lyssiotis; Steven P Gygi; Alex Toker; Lewis C Cantley; John M Asara; J Wade Harper; Wenyi Wei
Journal:  Mol Cell       Date:  2011-10-21       Impact factor: 17.970

4.  Regulation of G1 Cell Cycle Progression: Distinguishing the Restriction Point from a Nutrient-Sensing Cell Growth Checkpoint(s).

Authors:  David A Foster; Paige Yellen; Limei Xu; Mahesh Saqcena
Journal:  Genes Cancer       Date:  2010-11

5.  Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors.

Authors:  Mona L Gauthier; Hal K Berman; Caroline Miller; Krystyna Kozakeiwicz; Karen Chew; Dan Moore; Joseph Rabban; Yunn Yi Chen; Karla Kerlikowske; Thea D Tlsty
Journal:  Cancer Cell       Date:  2007-11       Impact factor: 31.743

6.  FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.

Authors:  Paolo Neviani; Ramasamy Santhanam; Joshua J Oaks; Anna M Eiring; Mario Notari; Bradley W Blaser; Shujun Liu; Rossana Trotta; Natarajan Muthusamy; Carlo Gambacorti-Passerini; Brian J Druker; Jorge Cortes; Guido Marcucci; Ching-Shih Chen; Nicole M Verrills; Denis C Roy; Michael A Caligiuri; Clara D Bloomfield; John C Byrd; Danilo Perrotti
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

7.  MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy.

Authors:  Bala S Balakumaran; Alessandro Porrello; David S Hsu; Wayne Glover; Adam Foye; Janet Y Leung; Beth A Sullivan; William C Hahn; Massimo Loda; Phillip G Febbo
Journal:  Cancer Res       Date:  2009-09-22       Impact factor: 12.701

8.  The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts.

Authors:  Angela C Hirbe; Anke J Roelofs; Desiree H Floyd; Hongju Deng; Stephanie N Becker; Lisa G Lanigan; Anthony J Apicelli; Zhiqiang Xu; Julie L Prior; Mark C Eagleton; David Piwnica-Worms; Michael J Rogers; Katherine Weilbaecher
Journal:  Bone       Date:  2009-01-23       Impact factor: 4.398

9.  C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells.

Authors:  D Zhuang; S Mannava; V Grachtchouk; W-H Tang; S Patil; J A Wawrzyniak; A E Berman; T J Giordano; E V Prochownik; M S Soengas; M A Nikiforov
Journal:  Oncogene       Date:  2008-08-04       Impact factor: 9.867

10.  Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis.

Authors:  Mark M Pomerantz; Yashaswi Shrestha; Richard J Flavin; Meredith M Regan; Kathryn L Penney; Lorelei A Mucci; Meir J Stampfer; David J Hunter; Stephen J Chanock; Eric J Schafer; Jennifer A Chan; Josep Tabernero; José Baselga; Andrea L Richardson; Massimo Loda; William K Oh; Philip W Kantoff; William C Hahn; Matthew L Freedman
Journal:  PLoS Genet       Date:  2010-11-11       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.